Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 4/20 | 0.51 |
| ▸ | PDE4A | P27815 | 4/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.51 |
| ▸ | PARG | Q86W56 | 9/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17434382 | 0.93 | PARG (0.60) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17434446 | 0.93 | CYP1A2 (0.60) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17434381 | 0.86 | MEN1 (0.51) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17434189 | 0.82 | CYP1A2 (0.56) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL20568859 | 0.80 | MAPT (0.43) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17434383 | 0.78 | PARG (0.48) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL17434620 | 0.78 | CYP1A2 (0.73) | PDE4APDE4BPDE4CPDE4DPARG | |
| SCHEMBL11857087 | 0.78 | MAPT (0.44) | PDE5APDE4APDE4BPDE4CPDE4D | |
| Bromide SCHEMBL8857427 | 0.77 | SIRT2 (0.46) | PARGCYP1A2KMT2AMAPTMEN1 | |
| SCHEMBL17969625 | 0.77 | CA12 (0.59) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-05 | — | — | US | disclosed |
| EP-3192791-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2975031-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229814-A1 | HETEROCYCLIC COMPOUND | RORB, RORC, RORA | PDE5A 1774/4885PDE4A 2341/4885PDE4B 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.